GH Research showcases Phase 2b GH001 posters at ASCP annual meeting

GH Research PLC (GHRS) — At the ASCP annual meeting (May 26-29 in Miami), GH Research presented three posters from its Phase 2b treatment-resistant depression trial of inhaled mebufotenin (GH001).

The data showed rapid, clinically meaningful reductions in depression and anhedonia versus placebo at Day 8, with benefits maintained through a six-month open-label extension and efficacy appearing independent of the number of prior antidepressant failures. The presentations reinforce the profile of GH001 ahead of pivotal Phase 3 work.

Source: stocktitan.net

For the rest of that week's sector news, read our week in review.